发明名称 INOSITOL DERIVATIVE AND USE OF THE SAME IN TREATMENT OF DISEASE CHARACTERIZED BY ABNORMAL PROTEIN FOLDING OR AGGREGATION OR AMYLOID FORMATION, DEPOSITION, ACCUMULATION OR PERSISTENCE
摘要 <P>PROBLEM TO BE SOLVED: To provide compounds, compositions and methods for treating diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence. <P>SOLUTION: Inositol derivatives represented by structural formula I wherein X is a radical of scyllo-inositol wherein R<SP POS="POST">1</SP>, R<SP POS="POST">2</SP>, R<SP POS="POST">3</SP>, R<SP POS="POST">4</SP>, R<SP POS="POST">5</SP>, and R<SP POS="POST">6</SP>are as defined in the specification, or pharmaceutically acceptable salts thereof are described. The compounds, compositions comprising the compounds and methods using the compounds for use in the prevention and/or treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence are also described. <P>COPYRIGHT: (C)2013,JPO&INPIT
申请公布号 JP2013018791(A) 申请公布日期 2013.01.31
申请号 JP20120235331 申请日期 2012.10.25
申请人 WARATAH PHARMACEUTICALS INC 发明人 CRUZ ANTONIO;KURDYDYK LINDA
分类号 A61K31/045;A61K31/047;A61K31/075;A61K31/12;A61K31/121;A61K31/13;A61K31/17;A61K31/19;A61K31/194;A61K31/215;A61K31/216;A61K31/22;A61K31/255;A61K31/357;A61K31/519;A61K31/6615;A61K31/7034;A61P1/04;A61P1/14;A61P3/02;A61P3/04;A61P3/10;A61P5/00;A61P7/00;A61P9/00;A61P9/10;A61P9/12;A61P9/14;A61P17/06;A61P19/02;A61P21/00;A61P21/04;A61P25/00;A61P25/02;A61P25/08;A61P25/14;A61P25/16;A61P25/18;A61P25/20;A61P25/22;A61P25/24;A61P25/26;A61P25/28;A61P25/32;A61P25/36;A61P29/00;A61P29/02;A61P31/04;A61P31/06;A61P31/08;A61P31/10;A61P31/12;A61P31/18;A61P31/22;A61P35/00;A61P43/00 主分类号 A61K31/045
代理机构 代理人
主权项
地址